600201 Jinyu Bio-Technology
- 9.83
- +0.01+0.10%
Jinyu Bio-Technology News
Biology Co., Ltd. (600201.SH): Jointly established “Inner Mongolia Centennial Synthetic Biotechnology Co., Ltd.” with leading domestic research teams
Gelonghui, May 9 | Biotech Co., Ltd. (600201.SH) said on the interactive platform that in 2023, the company will “take the lead in entering the era of innovative synthetic biology integrating biotechnology and information technology; advance into multiple multivalent vaccines, iterative vaccines, digital vaccines and novel drugs to overcome the 100-year challenge of the African swine fever vaccine; apply AI intelligence to provide the aquaculture industry with overall solutions for epidemic prevention and control, and use value marketing to improve quality and efficiency for users” as the company's development strategy. As a path support for achieving strategic goals, the company and leading domestic research teams jointly established “Inner Mongolia Centennial Synthetic Biotechnology Co., Ltd.” This creation
Biotech Co., Ltd. (600201): Non-oral products continue to gain strength and profits continue to improve
Matters: The company released the 2023 annual report and the 2024 quarterly report: achieved revenue of 1,598 million yuan, yoy +4.55%, net profit to mother of 284 million, yoy +34.64%, deducted 2.5 percent from non-return mother
Biotech Co., Ltd. (600201): Steady growth in the face of adversity, R&D investment reaps rewards
Performance summary: In 2023, the company achieved operating income of 1,598 billion yuan, +4.55% year-on-year, net profit to mother was 284 million yuan, +34.64% year-on-year, and net profit after deduction was 255 million yuan, year-on-year +
Bio Co., Ltd. (600201): Business quality continues to improve, and new products can be expected to be launched
Incident: The company announced its 2023 annual report and 2024 quarterly report. The company achieved a total operating income of 1,598 billion yuan, yoy 4.55%, and net profit to mother of 284 million yuan, yoy34.
Jinyu Bio-technology Co., Ltd. (SHSE:600201) Analysts Just Slashed This Year's Estimates
The analysts covering Jinyu Bio-technology Co., Ltd. (SHSE:600201) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year.
Express News | Biotech Co., Ltd.: The subsidiary obtained a new veterinary drug registration certificate
Biotech Co., Ltd. (600201): Improving profitability, R&D investment entering the harvest period
Event: On April 25, 2024, Biotech Co., Ltd. released its 2023 annual report and 2024 quarterly report: in 2023, the company achieved operating income of 1,598 billion yuan, an increase of 4.55% over the previous year, and net profit to mother2
Bio Co., Ltd. (600201): Non-foot-and-mouth disease products reinforce product matrix profitability and steady recovery
The 2023 and 1Q24 results are in line with our expectations, Biotech Co., Ltd. announced the 2023 and 1Q24 results: the company achieved revenue of 1,598/348 million yuan in 2023/1Q24, +4 year-on-year respectively.
Biotech Co., Ltd. (600201): Strong performance, strong performance, new products blossom, and the leader in animal insurance innovation continues to grow
The performance is resilient, and new products have blossomed more, and the leading animal insurance innovators continue to grow, maintaining the release of the 2023 annual report and the 2024 quarterly report by “buy” rating companies, with 2023 revenue of 1,598 billion yuan (+4.55%).
China Galaxy released a research report on April 25 stating that it gave Biotech Co., Ltd. (600201.SH) a recommended rating. The main reasons for the rating include: 1) the company's revenue & profit growth in 23, and steady performance in 24Q1; 2) the gr
China Galaxy released a research report on April 25 stating that it gave Biotech Co., Ltd. (600201.SH) a recommended rating. The main reasons for the rating include: 1) the company's revenue & profit growth in 23, and steady performance in 24Q1; 2) the gross margin of government harvesting increased significantly, and the growth rate of large individual pig seedlings was impressive; 3) continuous investment in research and development, and the world's first animal mRNA vaccine production workshop passed static inspection. (Mainichi Keizai Shimbun)
Bio Co., Ltd. (600201): Stable performance in 24Q1, gross margin showed an upward trend
Event: The company released its 2023 Annual Report & 2024 First Quarter Report. The company's revenue in '23 was 1,598 billion yuan, +4.55% year on year; net profit to mother was 284 million yuan, +34.64 million yuan year on year
Biotech Co., Ltd. (600201.SH) announced first-quarter results, net profit of 106 million yuan decreased by 1.05% year-on-year
Biotech Co., Ltd. (600201.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 348 million yuan, a year-on-year decrease of 4.42%; net profit attributable to shareholders of listed companies of 106 million yuan, a year-on-year decrease of 1.05%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 95.32%, a year-on-year decrease of 5.32%; and basic earnings per share.
Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Business Is Trailing The Market But Its Shares Aren't
With a price-to-earnings (or "P/E") ratio of 33.3x Jinyu Bio-technology Co., Ltd. (SHSE:600201) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E
Express News | Tiankang Biology: Chairman Yang Yan resigns because she has reached the legal retirement age
Biotech Co., Ltd. (600201): The traditional leading style of animal insurance continues to fully innovate and set sail again
Leading traditional animal health care, focusing on the field of herbal medicine. The company is one of the largest manufacturers of veterinary biological products in China. It is mainly engaged in R&D, production and sales of veterinary biological products. The product categories include pigs, poultry, ruminants and pets.
Is The Market Rewarding Jinyu Bio-technology Co., Ltd. (SHSE:600201) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
With its stock down 14% over the past three months, it is easy to disregard Jinyu Bio-technology (SHSE:600201). It is possible that the markets have ignored the company's differing financials and de
Express News | Feipeng Biotech's Venture Market IPO “crunch” was the first company to terminate the registration process in the Year of the Dragon
Express News | The Securities Regulatory Commission terminated Feipeng Biotech's issuance registration process, and the company and sponsoring agency voluntarily requested the withdrawal of registration application documents
Calculating The Intrinsic Value Of Jinyu Bio-technology Co., Ltd. (SHSE:600201)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Jinyu Bio-technology fair value estimate is CN¥6.57 With CN¥7.71 share price, Jinyu Bio-technology appears to be trading close to its estimat
Positive Earnings Growth Hasn't Been Enough to Get Jinyu Bio-technology (SHSE:600201) Shareholders a Favorable Return Over the Last Three Years
Jinyu Bio-technology Co., Ltd. (SHSE:600201) shareholders should be happy to see the share price up 15% in the last month. But that doesn't help the fact that the three year return is less impressi
Analysis
Price Target
No Data
